MCL1 and prostate cancer: In prostate cancer, the BH3-mimetic sabutoclax blocks the prosurvival BCL2 family member, myeloid cell leukemia-1 (MCL1), and activates the autophagic process to facilitate the induction of apoptosis mediated by NOXA and BIM [230].